These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1384 related items for PubMed ID: 18070147

  • 1. BRAF mutation associated with other genetic events identifies a subset of aggressive papillary thyroid carcinoma.
    Costa AM, Herrero A, Fresno MF, Heymann J, Alvarez JA, Cameselle-Teijeiro J, García-Rostán G.
    Clin Endocrinol (Oxf); 2008 Apr; 68(4):618-34. PubMed ID: 18070147
    [Abstract] [Full Text] [Related]

  • 2. Correlation between B-RAFV600E mutation and clinico-pathologic parameters in papillary thyroid carcinoma: data from a multicentric Italian study and review of the literature.
    Fugazzola L, Puxeddu E, Avenia N, Romei C, Cirello V, Cavaliere A, Faviana P, Mannavola D, Moretti S, Rossi S, Sculli M, Bottici V, Beck-Peccoz P, Pacini F, Pinchera A, Santeusanio F, Elisei R.
    Endocr Relat Cancer; 2006 Jun; 13(2):455-64. PubMed ID: 16728573
    [Abstract] [Full Text] [Related]

  • 3. Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations.
    Quiros RM, Ding HG, Gattuso P, Prinz RA, Xu X.
    Cancer; 2005 Jun 01; 103(11):2261-8. PubMed ID: 15880523
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Genotyping of an Italian papillary thyroid carcinoma cohort revealed high prevalence of BRAF mutations, absence of RAS mutations and allowed the detection of a new mutation of BRAF oncoprotein (BRAF(V599lns)).
    Carta C, Moretti S, Passeri L, Barbi F, Avenia N, Cavaliere A, Monacelli M, Macchiarulo A, Santeusanio F, Tartaglia M, Puxeddu E.
    Clin Endocrinol (Oxf); 2006 Jan 01; 64(1):105-9. PubMed ID: 16402937
    [Abstract] [Full Text] [Related]

  • 6. Aberrant BRAF splicing as an alternative mechanism for oncogenic B-Raf activation in thyroid carcinoma.
    Baitei EY, Zou M, Al-Mohanna F, Collison K, Alzahrani AS, Farid NR, Meyer B, Shi Y.
    J Pathol; 2009 Apr 01; 217(5):707-15. PubMed ID: 19156774
    [Abstract] [Full Text] [Related]

  • 7. Clinicopathologic features and BRAF(V600E) mutation analysis in cutaneous metastases from well-differentiated thyroid carcinomas.
    Erickson LA, Jin L, Nakamura N, Bridges AG, Markovic SN, Lloyd RV.
    Cancer; 2007 May 15; 109(10):1965-71. PubMed ID: 17387744
    [Abstract] [Full Text] [Related]

  • 8. No correlation between BRAFV600E mutation and clinicopathological features of papillary thyroid carcinomas in Taiwan.
    Liu RT, Chen YJ, Chou FF, Li CL, Wu WL, Tsai PC, Huang CC, Cheng JT.
    Clin Endocrinol (Oxf); 2005 Oct 15; 63(4):461-6. PubMed ID: 16181240
    [Abstract] [Full Text] [Related]

  • 9. BRAF mutations are associated with some histological types of papillary thyroid carcinoma.
    Trovisco V, Vieira de Castro I, Soares P, Máximo V, Silva P, Magalhães J, Abrosimov A, Guiu XM, Sobrinho-Simões M.
    J Pathol; 2004 Feb 15; 202(2):247-51. PubMed ID: 14743508
    [Abstract] [Full Text] [Related]

  • 10. BRAF mutations in an Italian cohort of thyroid cancers.
    Fugazzola L, Mannavola D, Cirello V, Vannucchi G, Muzza M, Vicentini L, Beck-Peccoz P.
    Clin Endocrinol (Oxf); 2004 Aug 15; 61(2):239-43. PubMed ID: 15272920
    [Abstract] [Full Text] [Related]

  • 11. BRAF, p53 and SOX2 in anaplastic thyroid carcinoma: evidence for multistep carcinogenesis.
    Gauchotte G, Philippe C, Lacomme S, Léotard B, Wissler MP, Allou L, Toussaint B, Klein M, Vignaud JM, Bressenot A.
    Pathology; 2011 Aug 15; 43(5):447-52. PubMed ID: 21716161
    [Abstract] [Full Text] [Related]

  • 12. High prevalence of BRAF mutation in a Brazilian cohort of patients with sporadic papillary thyroid carcinomas: correlation with more aggressive phenotype and decreased expression of iodide-metabolizing genes.
    Oler G, Cerutti JM.
    Cancer; 2009 Mar 01; 115(5):972-80. PubMed ID: 19152441
    [Abstract] [Full Text] [Related]

  • 13. The BRAF mutation is useful for prediction of clinical recurrence in low-risk patients with conventional papillary thyroid carcinoma.
    Kim TY, Kim WB, Rhee YS, Song JY, Kim JM, Gong G, Lee S, Kim SY, Kim SC, Hong SJ, Shong YK.
    Clin Endocrinol (Oxf); 2006 Sep 01; 65(3):364-8. PubMed ID: 16918957
    [Abstract] [Full Text] [Related]

  • 14. The BRAF mutation is not associated with poor prognostic factors in Korean patients with conventional papillary thyroid microcarcinoma.
    Kim TY, Kim WB, Song JY, Rhee YS, Gong G, Cho YM, Kim SY, Kim SC, Hong SJ, Shong YK.
    Clin Endocrinol (Oxf); 2005 Nov 01; 63(5):588-93. PubMed ID: 16268813
    [Abstract] [Full Text] [Related]

  • 15. Clinical significance of BRAF (V600E) mutation and Ki-67 labeling index in papillary thyroid carcinomas.
    Nakayama H, Yoshida A, Nakamura Y, Hayashi H, Miyagi Y, Wada N, Rino Y, Masuda M, Imada T.
    Anticancer Res; 2007 Nov 01; 27(5B):3645-9. PubMed ID: 17972530
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. The presence of BRAF point mutation in adult papillary thyroid carcinomas from atomic bomb survivors correlates with radiation dose.
    Takahashi K, Eguchi H, Arihiro K, Ito R, Koyama K, Soda M, Cologne J, Hayashi Y, Nakata Y, Nakachi K, Hamatani K.
    Mol Carcinog; 2007 Mar 01; 46(3):242-8. PubMed ID: 17186541
    [Abstract] [Full Text] [Related]

  • 20. BRAF (V600E) mutation analysis on liquid-based cytology-processed aspiration biopsies predicts bilaterality and lymph node involvement in papillary thyroid microcarcinoma.
    Rossi ED, Martini M, Capodimonti S, Lombardi CP, Pontecorvi A, Vellone VG, Zannoni GF, Larocca LM, Fadda G.
    Cancer Cytopathol; 2013 Jun 01; 121(6):291-7. PubMed ID: 23192956
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 70.